sage therapeutics seeking alpha:SAGE Sage Therapeutics

SAGE Sage Therapeutics

SAGE Sage Therapeutics

SAGESageTherapeutics,Inc.LatestComments.Follow.$12.000.50(+4.35...SeekingAlpha-PowertoInvestors.PowertoInvestors·RSSFeed·Sitemap·Group ...。其他文章還包含有:「SAGESageTherapeutics」、「SAGESageTherapeutics」、「SAGESageTherapeutics」、「SAGESageTherapeutics」、「SAGESageTherapeutics」、「SageTherapeuticsdipsafterCitiinitiatesatSell」、「SageTherapeuticsStock」、「SageTherapeutics」、「SageThe...

查看更多 離開網站

Provide From Google
SAGE Sage Therapeutics
SAGE Sage Therapeutics

https://seekingalpha.com

Find hidden gems and smart strategies from top experts when you join Seeking Alpha. Create free account. SAGE Sage Therapeutics, Inc. Earnings Date & History.

Provide From Google
SAGE Sage Therapeutics
SAGE Sage Therapeutics

https://seekingalpha.com

A high-level overview of Sage Therapeutics, Inc. (SAGE) stock. Stay up ... Seeking Alpha - Power to Investors. Power to Investors · RSS Feed · Sitemap · Group ...

Provide From Google
SAGE Sage Therapeutics
SAGE Sage Therapeutics

https://seekingalpha.com

A high-level overview of Sage Therapeutics, Inc. (SAGE) stock. Stay ... Find hidden gems and smart strategies from top experts when you join Seeking Alpha.

Provide From Google
SAGE Sage Therapeutics
SAGE Sage Therapeutics

https://seekingalpha.com

A high-level overview of Sage Therapeutics, Inc. (SAGE) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, ...

Provide From Google
SAGE Sage Therapeutics
SAGE Sage Therapeutics

https://seekingalpha.com

Sage Therapeutics, Inc. is currently approximately $10.82 per share. Should I buy SAGE or ERAS stock? SAGE's Wall Street analysts's rating summary for ...

Provide From Google
Sage Therapeutics dips after Citi initiates at Sell
Sage Therapeutics dips after Citi initiates at Sell

https://seekingalpha.com

Sage Therapeutics (NASDAQ:SAGE) initiated at Sell/High Risk by Citi as it believes the company will face outsized commercial, clinical, ...

Provide From Google
Sage Therapeutics Stock
Sage Therapeutics Stock

https://seekingalpha.com

Sage Therapeutics' investigational drug for Parkinson's disease, dalzanemdor, failed in a Phase 2 trial, leading to a 20% drop in the stock.

Provide From Google
Sage Therapeutics
Sage Therapeutics

https://seekingalpha.com

SAGE Sage Therapeutics, Inc. Latest News. Follow 11.25K followers. $10.75 ... © 2024 Seeking Alpha. To ensure this doesn't happen in the future, please ...

Provide From Google
Sage Therapeutics
Sage Therapeutics

https://seekingalpha.com

SAGE Sage Therapeutics, Inc. Price History & Data. Follow 11.26K followers ... © 2024 Seeking Alpha. To ensure this doesn't happen in the future, please ...